Sector News

Merck KGaA to buy Sigma-Aldrich for $17 billion

September 22, 2014
Life sciences
(Reuters) – German drugs and chemicals maker Merck KGaA (MRCG.DE) said on Monday it agreed to acquire Sigma-Aldrich (SIAL.O) for $17 billion (10.41 billion pounds) in cash to boost its life science business.
 
The deal, approved by Sigma-Aldrich’s management, will see Merck acquire all shares for $140 apiece in cash.
 
That represents a 37 percent premium over the latest closing price of $102.37 on Sept. 19 and a 36 percent premium to the one-month average closing price, according to Merck.
 
(Reporting by Ludwig Burger; Editing by Georgina Prodhan)

Related News

September 23, 2020

Novartis, Siemens to develop blood tests for multiple sclerosis

Life sciences

Siemens Healthineers has inked what it describes as a “master collaboration agreement” with Novartis to help provide diagnostic tests linked to therapies across the drugmaker’s pipeline. To start, the companies […]

September 22, 2020

GSK’s Zejula and AZ’s Lynparza leap toward broader EU approval

Life sciences

GlaxoSmithKline’s Zejula and AstraZeneca’s Lynparza have both moved towards EU approval in new indications after receiving positive opinions from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human […]

September 22, 2020

Roche acquires Irish biotech firm Inflazome

Life sciences

Swiss pharma company Roche is set to acquire Irish biotech firm Inflazome for an upfront payment of $449m (€380m). In addition to the upfront payment, Inflazome is also eligible to […]